

**ACTION:** Notice of information collection to be submitted to OMB for review and approval under the Paperwork Reduction Act.

**SUMMARY:** In accordance with requirements of the Paperwork Reduction Act of 1995 ("PRA"), 44 U.S.C. 3501 *et seq.*, the FDIC may not conduct or sponsor, and the respondent is not required to respond to, an information collection unless it displays a currently valid Office of Management and Budget (OMB) control number. The FDIC, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on the renewal of an existing information collection, as required by the PRA. On April 30, 2012 (77 FR 25479), the FDIC solicited public comment for a 60-day period on the renewal of the following information collection: Notice Regarding Assessment Credits (OMB No. 3064-0151). No comments were received. Therefore, the FDIC hereby gives notice of submission of its request for renewal to OMB for review.

**DATES:** Comments must be submitted on or before August 16, 2012.

**ADDRESSES:** Interested parties are invited to submit written comments to the FDIC by any of the following methods:

- <http://www.FDIC.gov/regulations/laws/federal/notices.html>.
- *Email:* [comments@fdic.gov](mailto:comments@fdic.gov) Include the name of the collection in the subject line of the message.
- *Mail:* Gary A. Kuiper (202.898.3877), Counsel, Room NYA-5046, Federal Deposit Insurance Corporation, 550 17th Street NW., Washington, DC 20429.
- *Hand Delivery:* Comments may be hand-delivered to the guard station at the rear of the 17th Street Building (located on F Street), on business days between 7:00 a.m. and 5:00 p.m.

All comments should refer to the relevant OMB control number. A copy of the comments may also be submitted to the OMB desk officer for the FDIC: Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Washington, DC 20503.

**FOR FURTHER INFORMATION CONTACT:** Gary A. Kuiper, at the FDIC address above.

**SUPPLEMENTARY INFORMATION:**

Proposal to renew the following currently-approved collection of information:

*Title:* Notice Regarding Assessment Credits.

*OMB Number:* 3064-0151.

*Frequency of Response:* Once.  
*Affected Public:* FDIC-insured institutions.  
*Estimated Number of Respondents:* 4.  
*Estimated Time per Response:* 2 hours.

*Estimated Total Annual Burden:* 8 hours.

*General Description of Collection:* FDIC-insured institutions must notify the FDIC if deposit insurance assessment credits are transferred, e.g., through a sale of the credits or through a merger, in order to obtain recognition of the transfer.

*Request for Comment*

Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the FDIC's functions, including whether the information has practical utility; (b) the accuracy of the estimates of the burden of the information collection, including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the information collection on respondents, including through the use of automated collection techniques or other forms of information technology. All comments will become a matter of public record.

Dated at Washington, DC, this 11th day of July 2012.

Federal Deposit Insurance Corporation.  
**Robert E. Feldman,**  
*Executive Secretary.*

[FR Doc. 2012-17308 Filed 7-16-12; 8:45 am]

**BILLING CODE 6714-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Meeting Notice for the President's Advisory Council on Faith-based and Neighborhood Partnerships**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the President's Advisory Council on Faith-based and Neighborhood Partnerships announces the following meeting:

*Name:* President's Advisory Council on Faith-based and Neighborhood Partnerships Council Meeting

*Time and Date:* Tuesday, July 31st 9:30 a.m.–12:00 p.m. (EST)

*Place:* Meeting will be held at a location to be determined in the White House complex, 1600 Pennsylvania Ave NW., Washington, DC. Space is extremely limited. Photo ID and RSVP are required to attend the event. Please RSVP to Ben O'Dell at [partnerships@hhs.gov](mailto:partnerships@hhs.gov).

There will also be a conference call line available for those who cannot attend the

meeting in person. The call-in line is: 1-877-568-4106, Passcode: 163-296-015.

*Status:* Open to the public, limited only by space available. Conference call limited only by lines available.

*Purpose:* The Council brings together leaders and experts in fields related to the work of faith-based and neighborhood organizations in order to: Identify best practices and successful modes of delivering social services; evaluate the need for improvements in the implementation and coordination of public policies relating to faith-based and other neighborhood organizations; and make recommendations for changes in policies, programs, and practices.

*Contact Person for Additional Information:* Please contact Ben O'Dell for any additional information about the President's Advisory Council meeting at [partnerships@hhs.gov](mailto:partnerships@hhs.gov).

*Agenda:* Please visit <http://www.whitehouse.gov/partnerships> for further updates on the Agenda for the meeting.

*Public Comment:* There will be an opportunity for public comment at the end of the meeting from 11:30-12 noon (EST). Comments and questions can be asked over the conference call line, or sent in advance to [partnerships@hhs.gov](mailto:partnerships@hhs.gov).

Dated: July 12, 2012.

**Ben O'Dell,**

*Designated Federal Officer and Associate Director, HHS Center for Faith-based and Neighborhood Partnerships.*

[FR Doc. 2012-17358 Filed 7-16-12; 8:45 am]

**BILLING CODE 4154-07-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2011-N-0708]

**Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Form FDA 3728, Animal Generic Drug User Fee Act Cover Sheet**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by August 16, 2012.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs,

OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov). All comments should be identified with the OMB control number 0910-0632. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Denver Presley II, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-3793.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

**Form FDA 3728, Animal Generic Drug User Fee Act Cover Sheet—21 U.S.C. 379j-21 (OMB Control Number 0910-0632)—Extension**

Section 741 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 379j-21) establishes three different kinds of user fees: (1) Fees for certain types of abbreviated applications for generic new animal drugs, (2) annual fees for certain generic new animal drug products, and (3) annual fees for certain sponsors of abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (21 U.S.C. 379j-21(a)). Because the submission of user fees concurrent with applications is required, the review of an application

cannot begin until the fee is submitted. Form FDA 3728 is the Animal Generic Drug User Fee Act (AGDUFA) Cover Sheet, which is designed to provide the minimum necessary information to determine whether a fee is required for review of an application, to determine the amount of the fee required, and to account for and track user fees.

In the **Federal Register** of October 5, 2011 (76 FR 61709), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN <sup>1</sup>

FDA Form Number	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
3728 .....	20	2	40	.08 (5 min.)	3.2

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

Respondents to this collection of information are generic animal drug applicants. Based on FDA's database system, there are an estimated 20 sponsors of new animal drugs potentially subject to AGDUFA.

Dated: July 12, 2012.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2012-17369 Filed 7-16-12; 8:45 am]

**BILLING CODE 4160-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2012-N-0001]

**Use of Influenza Disease Models To Quantitatively Evaluate the Benefits and Risks of Vaccines: A Technical Workshop; Public Workshop**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop.

The Food and Drug Administration (FDA) is announcing a public workshop entitled: "Use of Influenza Disease Models to Quantitatively Evaluate the Benefits and Risks of Vaccines: A Technical Workshop." The purpose of this public workshop is to provide stakeholders a forum to discuss the design of a model to quantitatively estimate the benefits and risks of a

hypothetical influenza vaccine, and to seek from a range of experts, feedback on the current version of the model used by the Center for Biologics Evaluation and Research (CBER) and suggestions for further development.

The public workshop will include presentations and panel discussions with experts from academia, regulated industry, government, and other stakeholders.

**Date and Time:** The public workshop will be held on August 23, 2012, from 9 a.m. to 4 p.m.

**Location:** The public workshop will be held at the Bethesda North Marriott Hotel & Conference Center; 5701 Marinelli Rd., Bethesda, MD 20852; 301-822-9200.

**Contact Person:** Richard Forshee, Center for Biologics Evaluation and Research (HF210), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-6042, email: [Richard.Forshee@fda.hhs.gov](mailto:Richard.Forshee@fda.hhs.gov).

**Registration:** Mail, fax, or email your registration information (including name, title, firm name, address, telephone, and fax numbers, and email address) to Richard Forshee (see *Contact Person*) by August 16, 2012. There is no registration fee for the public workshop. Early registration is recommended because seating is limited. Registration on the day of the public workshop will be provided on a space-available basis beginning at 8 a.m. If you need special accommodations due to a disability,

please contact Richard Forshee (see *Contact Person*) at least 7 days in advance.

**SUPPLEMENTARY INFORMATION:** The workshop will provide an opportunity for discussions on the application of open source influenza infectious disease computer simulation models to generate quantitative estimates of the benefits and risks of influenza vaccination.

The public workshop presentations and panel discussions will: (1) Discuss recent developments in open-source, agent-based, publicly available computer simulation tools to model influenza and other infectious diseases; (2) discuss and seek technical feedback on the CBER quantitative model of influenza vaccine benefit/risk; and (3) discuss possible applications of quantitative benefit/risk assessment methods to vaccine assessment of quantitative benefit/risk assessment methods to vaccine assessment.

**Transcripts:** Please be advised that as soon as possible after a transcript of the public workshop is available, it will be accessible at: <http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/TranscriptsMinutes/default.htm>. Transcripts of the public workshop may also be requested in writing from the Division of Freedom of Information (ELEM-1029), Food and Drug Administration, 12420 Parklawn Dr., Rockville, MD 20857.